Novelos Therapeutics Announces Positive Phase 2 Results in NOV-002 Neoadjuvant Breast Cancer Trial at Sylvester Comprehensive Cancer Center, at the University of Miami
Tumor Response Target Achieved – Detailed Results Submitted for Presentation at SABCS in December 2010
NEWTON, Mass.--(BUSINESS WIRE)--Novelos Therapeutics, Inc. (OTCBB: NVLT), a biopharmaceutical company developing therapeutics to treat cancer...
Sequential doxorubicin, cyclophosphamide, docetaxel had the best outcomes for OS and PFS in women with early breast cancer.
Results of the National Surgical Adjuvant Breast and Bowel Project B-30 trial indicate that the use of sequential doxorubicin plus cyclophosphamide followed by docetaxel — or sequential ACT — improved DFS in patients with early-stage breast cancer compared with the use of concurrent ACT. In addition, sequential ACT also improved...
Cyclophosphamide, methotrexate and 5-FU chemotherapy produced the greatest magnitude of benefit for patients with triple-negative breast cancer, results from International Breast Cancer Study Group trials VIII and IX showed.
“Recognition of factors predictive of response has become crucial for understanding treatment effects in the adjuvant treatment of breast cancer,” researchers wrote. “We demonstrated that the magnitude of the effect of chemotherapy...
EMEND(R) indication updated by Health Canada includes broader group of women patients
MONTREAL, May 26 /CNW Telbec/ - More women fighting cancers such as breast, lung, colorectal and ovarian can now help prevent the nausea and vomiting associated with their treatment of moderately emetogenic (vomit-inducing) cancer chemotherapy (MEC). Although new treatment entities have been developed in the past 10 years for control of chemically-induced nausea and vomiting (CINV), CINV remains a...
SILVER SPRING, Md., Feb. 18 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Rituxan (rituximab) to treat certain patients with chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer.
Rituxan, an anti-cancer drug, is intended for patients with CLL who are beginning chemotherapy for the first time and for those who have not responded to other cancer drugs for CLL. Rituxan is administered with two other chemotherapy drugs,...
